Generics maker Sandoz says president should focus on tactic of ‘evergreening’ pricier products in his drive to lower costs
The president seeks to lower US rates in line with other nations but his directive lacks enforcement power
The US is the biggest market for prescription drugs, accounting for roughly $600bn of annual sales out of a global $1tn or so
Trump sets out plans for cost targets and eliminating ‘middlemen’ in executive order
President promises to defy industry pressure and drastically cut cost of pharmaceuticals
Novartis and Sanofi CEOs push for European benchmark against US prices
Vast majority of drugs prescribed in America are off-patent generics made in lower-cost countries
Latest executive order could shake up US pharma industry
Under the scheme, drugmakers discount price of medicines sold in bulk to healthcare system
Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Anaesthetics are not putting patients to sleep, doctors warn, in call for greater access to foreign medicine
Pharma groups say higher levy will stifle growth of life sciences
Novo Nordisk shares hit as government adds blockbuster weight-loss treatments to new round of negotiations
Federal Trade Commission says companies ‘hiked costs’ for medicines, including cancer and HIV treatments
Funding for existing services would have helped more patients
State-backed insurance programmes would fund drugs for obese patients without separate health conditions
European Commission says company abused ‘dominant position’ to ‘artificially’ extend patent protection of MS medicine Copaxone
Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
Senator Bernie Sanders accuses Ozempic and Wegovy maker of ‘ripping off’ Americans
Complaint alleges pharmacy benefit managers owned by CVS, Cigna and UnitedHealth are keeping prices high
US telehealth groups including Hims & Hers and Ro could find new revenue streams under threat
US group races to overcome production bottleneck to meet demand for anti-obesity medicine Zepbound
Easing the squeeze on the share of health spending that goes on medicine may alleviate pain
Spending watchdog declines to give green light to lecanemab for patients in England
